Artificial intelligence unifies knowledge and actions in drug repositioning.
Artificial intelligence unifies knowledge and actions in drug repositioning.
复制标题
DOI：
10.1042/etls20210223
复制
发表时间：
2021-12-21
影响因子：
3.8
通讯作者：
Wong STC
中科院分区：
文献类型：
--
作者：
Yin Z;Wong STC
药物重新定位旨在重新使用现有药物、搁置药物或临床试验失败的候选药物用于其他医学适应症。它的吸引力来自于降低与新药安全性测试相关的风险，以及将已知药物投入临床的时间。人工智能（AI）最近一直在寻求加快药物的重新定位和发现。人工智能在药物重新定位中的本质是统一知识和行动，即结合现实世界和实验数据，以制定最佳的前进方向，以确定针对疾病的有效疗法。在这篇综述中，我们对AI和药物重新定位的发展抱有积极的期望，并总结了AI在药物重新定位的几种方法中的作用。
Drug repositioning aims to reuse existing drugs, shelved drugs, or drug candidates that failed clinical trials for other medical indications. Its attraction is sprung from the reduction in risk associated with safety testing of new medications and the time to get a known drug into the clinics. Artificial Intelligence (AI) has been recently pursued to speed up drug repositioning and discovery. The essence of AI in drug repositioning is to unify the knowledge and actions, i.e. incorporating real-world and experimental data to map out the best way forward to identify effective therapeutics against a disease. In this review, we share positive expectations for the evolution of AI and drug repositioning and summarize the role of AI in several methods of drug repositioning.